arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Bio-Rad Laboratories, Inc.

BIO Industrials Biotechnology: Laboratory Analytical Instruments
$363.50
▲ +2.5% Today
as of Oct 22, 16:46 ET
Last 30 days -1.37% Sep 14 → Oct 22
$350.04 $360.11 $370.18 $380.25 $390.32 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$359.83
High
$367.93
Low
$360.65
Volume
$228,219
Avg Vol
$287,015
Mkt Cap
$9.8B
P/E (TTM)
—
Beta
—
52w High
$396.23
52w Low
$236.73
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 9 items

Oct 14 · 13:00 PR Business Wire
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
Oct 1 · 00:09 Simply Wall St.
Why Bio Rad Laboratories (BIO) Is Back In The Spotlight
Sep 26 · 03:02 MarketBeat
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
▸ Show all 9 press releases & news Free account →

BIO earnings at a glance

Bio-Rad Laboratories, Inc. (BIO) is scheduled to report earnings on Wednesday, November 4, 2026 — in 12 days. Analysts expect earnings per share of $2.61, compared with $2.26 in the same quarter last year (+15%). The options market is pricing a move of about ±3.9% after the report, a range of roughly $349.40 to $377.60 from today's $363.50. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±8.2% on average; after the most recent report on Aug 4, 2026 it moved +4.5%. That means options currently expect less movement than BIO has typically delivered. BIO beat the consensus EPS estimate in 3 of its last 6 reported quarters. Implied volatility is currently 33%. The share price of $363.50 sits in the middle of its 52-week range.

More Industrials stocks · All stocks · Earnings calendar

Overview

52-week range
$237
$396
79% of range
Avg surprise (last 6)
+9.7%
Avg reaction (last 6)
-0.8%
33% positive
Latest IV / EM
33%
EM ±3.9% · $360 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-76.26$-51.36$-26.46$-1.56$23.34 Actual $13.45Actual $-76.26Actual $23.34Actual $2.54Est $1.73Actual $2.61Est $1.93Actual $2.26Est $2.30Actual $2.51Est $2.57Actual $1.89Est $2.77Actual $2.62Est $2.34 MarJunSepMar/2025Jun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$-527M$-224M$79M$383M$686M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Aug 4, 2026Jun/2026 $2.62 $2.34 +12.0% -10.3% +4.5% earnings
Thu Apr 30, 20268K 2026-04-30 $1.89 $2.77 -31.8% — -8.4% earnings
Thu Feb 12, 20268K 2026-02-12 $2.51 $2.57 -2.3% — -12.3% earnings
Wed Oct 29, 2025Sep/2025 $2.26 $2.30 -1.7% — -4.7% earnings
Thu Jul 31, 2025Jun/2025 $2.61 $1.93 +35.2% — +17.6% earnings
Thu May 1, 2025Mar/2025 $2.54 $1.73 +46.8% — -1.7% earnings
Mon Sep 30, 2024Sep 2024 $23.34 — — — — financials
Sun Jun 30, 2024Jun 2024 $-76.26 — — — — financials
Sun Mar 31, 2024Mar 2024 $13.45 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Wed Nov 4, 2026Sep/2026OTHER $2.61$2.26 +15.5%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$651M$592M—$653M$652M$585M—$650M
Cost of revenue$305M$283M—$310M$306M$279M—$294M
Gross profit$346M$309M—$343M$345M$306M—$356M
Operating income$73M$34M—$65M$77M$24M—$64M
Net income$371M$-527M—$-342M$318M$64M—$653M
EPS (diluted)$13.85$-19.55—$-12.70$11.67$2.29—$23.34

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$517M$507M$530M$396M$369M$521M$488M$410M
Inventory$781M$770M$741M$783M$799M$790M$760M$804M
Total current assets$3.02B$2.94B$2.91B$2.84B$2.81B$3.04B$3.03B$3.06B
Total assets$10.25B$9.79B$10.58B$9.70B$10.21B$9.53B$9.36B$10.60B
Long-term debt$803M$803M$1.20B$1.20B$1.20B$1.20B$1.20B$1.20B
Total liabilities$3.08B$2.94B$3.12B$2.96B$3.09B$2.85B$2.79B$3.12B
Total equity$7.17B$6.85B$7.45B$6.74B$7.13B$6.68B$6.57B$7.49B

Implied volatility — last 90 days

24%47%71%94%117% Jun 07 — IV 45% · EM ±6.3%Jun 08 — IV 43% · EM ±5.6%Jun 09 — IV 45% · EM ±5.7%Jun 10 — IV 43% · EM ±5.1%Jun 11 — IV 43% · EM ±4.8%Jun 12 — IV 38% · EM ±3.9%Jun 15 — IV 43% · EM ±3.1%Jun 16 — IV 56% · EM ±3.3%Jun 17 — IV 118% · EM ±4.9%Jun 19 — IV 36% · EM ±7.9%Jun 22 — IV 36% · EM ±7.5%Jun 23 — IV 38% · EM ±7.9%Jun 24 — IV 38% · EM ±7.7%Jun 25 — IV 40% · EM ±7.8%Jun 26 — IV 36% · EM ±7.0%Jun 29 — IV 39% · EM ±6.8%Jun 30 — IV 38% · EM ±6.5%Jul 01 — IV 37% · EM ±6.2%Jul 02 — IV 35% · EM ±5.7%Jul 03 — IV 37% · EM ±5.7%Jul 06 — IV 38% · EM ±5.3%Jul 07 — IV 40% · EM ±5.3%Jul 08 — IV 41% · EM ±5.2%Jul 09 — IV 42% · EM ±4.9%Jul 10 — IV 38% · EM ±4.2%Jul 13 — IV 48% · EM ±4.0%Jul 14 — IV 52% · EM ±3.8%Jul 15 — IV 65% · EM ±3.8%Jul 16 — IV 80% · EM ±3.4%Jul 20 — IV 53% · EM ±12.5%Jul 21 — IV 51% · EM ±11.9%Jul 22 — IV 52% · EM ±11.9%Jul 23 — IV 51% · EM ±11.5%Jul 24 — IV 52% · EM ±11.5%Jul 27 — IV 53% · EM ±11.2%Jul 28 — IV 55% · EM ±11.3%Jul 29 — IV 54% · EM ±10.8%Jul 30 — IV 54% · EM ±10.5%Jul 31 — IV 54% · EM ±10.4%Aug 03 — IV 54% · EM ±9.6%Aug 04 — IV 55% · EM ±9.5%Aug 05 — IV 36% · EM ±6.0%Aug 06 — IV 33% · EM ±5.4%Aug 07 — IV 33% · EM ±5.1%Aug 10 — IV 34% · EM ±4.8%Aug 11 — IV 29% · EM ±3.9%Aug 12 — IV 32% · EM ±4.0%Aug 13 — IV 28% · EM ±3.3%Aug 14 — IV 37% · EM ±4.1%Aug 17 — IV 35% · EM ±2.9%Aug 18 — IV 44% · EM ±3.1%Aug 19 — IV 60% · EM ±3.5%Aug 20 — IV 71% · EM ±3.0%Aug 24 — IV 28% · EM ±5.9%Aug 25 — IV 28% · EM ±5.8%Aug 26 — IV 29% · EM ±5.9%Aug 27 — IV 29% · EM ±5.7%Aug 28 — IV 30% · EM ±5.7%Aug 31 — IV 28% · EM ±5.0%Sep 01 — IV 29% · EM ±4.9%Sep 02 — IV 31% · EM ±5.2%Sep 03 — IV 25% · EM ±4.0%Sep 04 — IV 30% · EM ±4.7%Sep 07 — IV 34% · EM ±4.7%Sep 08 — IV 33% · EM ±4.4%Sep 09 — IV 33% · EM ±4.2%Sep 10 — IV 32% · EM ±3.8%Sep 11 — IV 32% · EM ±3.5%Sep 14 — IV 35% · EM ±2.9%Sep 15 — IV 45% · EM ±3.3%Sep 16 — IV 42% · EM ±2.5%Sep 17 — IV 62% · EM ±2.6%Sep 21 — IV 28% · EM ±5.9%Sep 22 — IV 28% · EM ±5.7%Sep 23 — IV 29% · EM ±5.8%Sep 24 — IV 29% · EM ±5.6%Sep 25 — IV 29% · EM ±5.6%Sep 28 — IV 30% · EM ±5.4%Sep 29 — IV 31% · EM ±5.3%Sep 30 — IV 29% · EM ±4.8%Oct 01 — IV 33% · EM ±5.3%Oct 02 — IV 32% · EM ±4.9%Oct 06 — IV 34% · EM ±4.5%Oct 07 — IV 34% · EM ±4.3%Oct 08 — IV 33% · EM ±3.9%

Sector peers

TXG
10x Genomics, Inc.
$9.9B $69.75-2.4%
AVTR
Avantor, Inc.
$10.4B $17.15+3.2%
BRKR
Bruker Corporation
$9.1B $57.31+2.5%
RVTY
Revvity, Inc.
$17.1B $157.36+0.9%
ALMR
Alamar Biosciences, Inc.
$1.9B $29.72+5.5%
PACB
Pacific Biosciences of California, Inc.
$845M $2.06+5.1%

BIO earnings FAQ

When is BIO's next earnings date?

Bio-Rad Laboratories, Inc. is expected to report on November 4, 2026.

What is BIO's expected move for earnings?

Options currently price a move of about ±3.9%, or $14.10 per share either way from $363.50.

How does BIO stock usually react to earnings?

Across the last 6 reports the average next-day move was ±8.2%, up 2 times and down 4 times.

What EPS are analysts expecting from Bio-Rad Laboratories, Inc.?

The consensus estimate is $2.61 per share, versus $2.26 a year ago.

What is BIO's implied volatility?

BIO's at-the-money implied volatility is about 33% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in